ADB-5'Br-BUTINACA

Last updated
ADB-5'Br-BUTINACA
ADB-5'Br-BUTINACA structure.png
Identifiers
  • N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-5-bromo-1-butylindazole-3-carboxamide
PubChem CID
ChemSpider
Chemical and physical data
Formula C18H25BrN4O2
Molar mass 409.328 g·mol−1
3D model (JSmol)
  • NC(=O)[C@@H](NC(=O)c1nn(CCCC)c2ccc(Br)cc21)C(C)(C)C
  • InChI=1S/C18H25BrN4O2/c1-5-6-9-23-13-8-7-11(19)10-12(13)14(22-23)17(25)21-15(16(20)24)18(2,3)4/h7-8,10,15H,5-6,9H2,1-4H3,(H2,20,24)(H,21,25)/t15-/m1/s1
  • Key:DIOILIVJIIJFPO-OAHLLOKOSA-N

ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug, [1] first detected in Philadelphia in the US in May 2022, [2] and subsequently found in South Korea, [3] Portugal and Sweden. [4] It is specifically listed as an illegal drug in Italy, [5] South Korea [6] and several states in the US, [7] [8] and controlled under analogue legislation in various other jurisdictions.

See also

References

  1. ↑ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. 16 (6): 616–628. doi:10.1002/dta.3592. PMID   37903509. S2CID   264671035.
  2. ↑ "ADB-5'Br-BINACA" (PDF). CFSRE Chemistry Report. The Center for Forensic Science Research & Education.
  3. ↑ Kim J, Yum H, Kang S, Lee N, Song J, Park Y, Choe S, Park M (November 2023). "Comprehensive evaluation of drug cases in Seoul and its metropolitan areas - 2022". Forensic Science International. 353 111877. doi:10.1016/j.forsciint.2023.111877. PMID   37989071. S2CID   265022768.
  4. ↑ "Yttrande enligt 13 § Lag (2011:111) om förstörande av vissa hälsofarliga missbrukssubstanser" [Opinion according to § 13 Act (2011:111) on the destruction of certain substances of abuse dangerous to health](PDF) (in Swedish). The Public Health Authority.
  5. ↑ "Aggiornamento delle tabelle contenenti l'indicazione delle sostanze stupefacenti e psicotrope, di cui al decreto del Presidente della Repubblica 9 ottobre 1990, n. 309 e successive modificazioni e integrazioni. Inserimento nella Tabella I di nuove sostanze psicoattive. (23A01072)" [Update of the tables containing the indication of the substances narcotic and psychotropic drugs, referred to in the decree of the President of the Republic 9 October 1990, n. 309 and subsequent amendments e integrations. Inclusion of new substances in Table I psychoactive. (23A01072)] (in Italian). Italy: Ministry of Health. 13 February 2023.
  6. ↑ "˝에이디비-5'비알-부티나카˝ 등 3종 임시마약류 지정예고" [Announcement of temporary designation of 3 types of narcotics, including “ADB-5 ‘BR-Butinaka’”]. Korean Food and Drug Daily News (in Korean).
  7. ↑ "18VAC110-20-322. Placement of chemicals in Schedule I." Administrative Code. Commonwealth of Virginia.
  8. ↑ "Section 19-03.1-05 - Schedule I, N.D. Cent. Code § 19-03.1-05". North Dakota Century Code. Archived from the original on November 25, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.